Oliver Sieber

Prof. Oliver Sieber

Laboratory Head in the Personalised Oncology Division at the Walter and Eliza Hall Institute of Medical Research (WEHI) and Honorary Associate Professor at the University of Melbourne, Melbourne, Australia
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2015 in Proteomics
Verified
Journal Article
Closed access
PDF file
MPMohashin Pathan
Mohashin Pathan
SKShivakumar Keerthikumar
Shivakumar Keerthikumar
CAChing‐Seng Ang
Ching‐Seng Ang
LGLahiru Gangoda
Lahiru Gangoda
CQCamelia Y.J. Quek
Camelia Y.J. Quek
Suresh MathivananSuresh Mathivanan
Suresh Mathivanan

31 March 2011 in Cancer
Verified
Journal Article
Open access
PDF file
BTBen Tran
Ben Tran
SKScott Kopetz
Scott Kopetz
JTJeanne Tie
Jeanne Tie
PGPeter Gibbs
Peter Gibbs
ZJZhi‐Qin Jiang
Zhi‐Qin Jiang
Jayesh DesaiJayesh Desai
Jayesh Desai
BACKGROUND: It is hypothesized that BRAF mutant cancers represent a discrete subset of metastatic colorectal cancer (CRC) defined by poorer survival. This study investigates whether BRAF mutant CRC is further defined by a distinct pattern of metastatic spread and explores the impact of BRAF mutation and microsatellite instability (MSI) on prognosis in metastatic CRC.METHODS: By using prospective clinical data and molecular analyses from 2 major centers (Royal Melbourne Hospital and The University of Texas MD Anderson Cancer Center), patients with known BRAF mutation status were analyzed for clinical characteristics, survival, and metastatic sites.RESULTS: The authors identified 524 metastatic CRC patients where BRAF mutation status was known; 57 (11%) were BRAF mutant tumors. BRAF mutant tumors were significantly associated with right‐sided primary tumor, MSI, and poorer survival (median, 10.4 months vs 34.7 months, P < .001). A distinct pattern of metastatic spread was observed in BRAF mutant tumors, namely higher rates of peritoneal metastases (46% vs 24%, P = .001), distant lymph node metastases (53% vs 38%, P = .008), and lower rates of lung metastases (35% vs 49%, P = .049). In additional survival analyses, MSI tumors had significantly poorer survival compared with microsatellite stable tumors (22.1 months vs 11.1 months, P = .017), but this difference was not evident in the BRAF mutant population.CONCLUSIONS: The pattern of metastatic spread observed in this study further defines BRAF mutant CRC as a discrete disease subset. The authors demonstrated that, unlikely early stage disease, MSI is associated with poorer survival in metastatic CRC, although this is driven by its association with BRAF mutation. Cancer 2011;. © 2011 American Cancer Society.

27 February 2003 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
Oliver SieberOliver Sieber
Oliver Sieber
LLLara Lipton
Lara Lipton
MCMichael Crabtree
Michael Crabtree
KHKarl Heinimann
Karl Heinimann
PFPaulo Fidalgo
Paulo Fidalgo
ITIan P.M. Tomlinson
Ian P.M. Tomlinson
Germ-line mutations in the base-excision–repair gene MYH have been associated with recessive inheritance of multiple colorectal adenomas. Tumors from affected persons displayed excess somatic transversions of a guanine–cytosine pair to a thymine–adenine pair (G:C→T:A) in the APC gene. We screened for germ-line MYH mutations in 152 patients with multiple (3 to 100) colorectal adenomas and 107 APC-mutation–negative probands with classic familial adenomatous polyposis (>100 adenomas). Subgroups were analyzed for changes in the related genes MTH1 and OGG1. Adenomas were tested for somatic APC mutations. Six patients with multiple adenomas and eight patients with polyposis had biallelic germline MYH variants. Missense and protein-truncating mutations were found, and the spectrums of mutations were very similar in the two groups of patients. In the tumors of carriers of biallelic mutations, all somatic APC mutations were G:C→T:A transversions. In the group with multiple adenomas, about one third of patients with more than 15 adenomas had biallelic MYH mutations. In the polyposis group, no patient with biallelic MYH mutations had severe disease (>1000 adenomas), but three had extracolonic disease. No clearly pathogenic MTH1 or OGG1 mutations were identified. Germ-line MYH mutations predispose persons to a recessive phenotype, multiple adenomas, or polyposis coli. For patients with about 15 or more colorectal adenomas — especially if no germ-line APC mutation has been identified and the family history is compatible with recessive inheritance — genetic testing of MYH is indicated for diagnosis and calculation of the level of risk in relatives. Clinical care of patients with biallelic MYH mutations should be similar to that of patients with classic or attenuated familial adenomatous polyposis.

8 July 2007 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TCthe CORGI Consortium
the CORGI Consortium
ITIan Tomlinson
Ian Tomlinson
EWEmily Webb
Emily Webb
LCLuis Carvajal-Carmona
Luis Carvajal-Carmona
PBPeter Broderick
Peter Broderick
Richard HoulstonRichard Houlston
Richard Houlston

1 February 2014 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
SDSally M. Dewhurst
Sally M. Dewhurst
NMNicholas McGranahan
Nicholas McGranahan
RBRebecca A. Burrell
Rebecca A. Burrell
ARAndrew J. Rowan
Andrew J. Rowan
EGEva Grönroos
Eva Grönroos
CSCharles Swanton
Charles Swanton
The contribution of whole-genome doubling to chromosomal instability (CIN) and tumor evolution is unclear. We use long-term culture of isogenic tetraploid cells from a stable diploid colon cancer progenitor to investigate how a genome-doubling event affects genome stability over time. Rare cells that survive genome doubling demonstrate increased tolerance to chromosome aberrations. Tetraploid cells do not exhibit increased frequencies of structural or numerical CIN per chromosome. However, the tolerant phenotype in tetraploid cells, coupled with a doubling of chromosome aberrations per cell, allows chromosome abnormalities to evolve specifically in tetraploids, recapitulating chromosomal changes in genomically complex colorectal tumors. Finally, a genome-doubling event is independently predictive of poor relapse-free survival in early-stage disease in two independent cohorts in multivariate analyses [discovery data: hazard ratio (HR), 4.70, 95% confidence interval (CI), 1.04–21.37; validation data: HR, 1.59, 95% CI, 1.05–2.42]. These data highlight an important role for the tolerance of genome doubling in driving cancer genome evolution. Significance: Our work sheds light on the importance of whole-genome–doubling events in colorectal cancer evolution. We show that tetraploid cells undergo rapid genomic changes and recapitulate the genetic alterations seen in chromosomally unstable tumors. Furthermore, we demonstrate that a genome-doubling event is prognostic of poor relapse-free survival in this disease type. Cancer Discov; 4(2); 175–85. ©2014 AACR. This article is highlighted in the In This Issue feature, p. 131

14 October 2007 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MCmembers of the CORGI Consortium
members of the CORGI Consortium
PBPeter Broderick
Peter Broderick
LCLuis Carvajal-Carmona
Luis Carvajal-Carmona
APAlan M Pittman
Alan M Pittman
EWEmily Webb
Emily Webb
Richard HoulstonRichard Houlston
Richard Houlston